Allogene Therapeutics (NASDAQ: ALLO) notice to sell 2,867 shares
Rhea-AI Filing Summary
Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares reflect the vesting of a restricted stock unit award dated 03/31/2026 granted under the issuer's equity compensation plan.
Positive
- None.
Negative
- None.
Insights
Form 144 lists a small post-vesting sale notice for vested RSUs.
The filing records the vesting of 2,867 restricted stock units on 03/31/2026 and a Form 144 notice dated 04/01/2026 proposing resale via Morgan Stanley Smith Barney LLC. This is a routine transfer of vested compensation.
Cash‑flow treatment and pricing details are not provided in the excerpt; subsequent transaction filings will state actual sale amounts and proceeds.